Phase I trial shows PD-1 blockade improves CAR-T effectiveness in large B-cell lymphoma, suggesting enhanced anti-tumor immunity in the tumor microenvironment.
Key Points
Evaluate the combined effects of PD-1 blockade and IL-7/CCL19 armored CAR-T therapy in patients with large B-cell lymphoma.
Conducted a phase I trial with 20 patients with relapsed/refractory large B-cell lymphoma.
Integrated PD-1 blockade with fourth-generation CAR-T therapy targeting CD19.
Utilized single-cell RNA sequencing to analyze CAR-T cell dynamics post-infusion.
PD-1 blockade converted 66.7% of partial responders to durable complete response.
Median progression-free survival of 60.0% and overall survival of 71.1% at 24 months.
Enhanced CAR-T cell persistence and tumor infiltration were observed with combined therapy.